(Q36747219)

16 August 2017

1 reference

title

Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions (English)

1 reference

16 August 2017

Søren M Bentzen

1

1 reference

16 August 2017

Paul M Harari

series ordinal

2

1 reference

16 August 2017

Jacques Bernier

series ordinal

3

1 reference

16 August 2017

1 March 2007

1 reference

Nature Clinical Practice Oncology

16 August 2017

1 reference

16 August 2017

4

1 reference

16 August 2017

172-180

1 reference

16 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/ncponc0744

16 August 2017

0 references

cites work

Early morbidity after radiotherapy with or without chemotherapy in advanced head and neck cancer. Experience from four nonrandomized studies.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer--a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

Radiotherapy: what can be achieved by technical improvements in dose delivery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

Improved outlook for Ewing's sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Treatment of Ewing's sarcoma with concurrent radiotherapy and chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology?

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Biologic basis for combining drugs with radiation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Early and Late Normal-tissue Injury after Postmastectomy Radiotherapy Alone or Combined with Chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

The Need for Adverse Effects Reporting Standards in Oncology Clinical Trials

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Repopulation of cancer cells during therapy: an important cause of treatment failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Repopulation in radiation oncology: perspectives of clinical research

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Use of conventional radiation therapy as part of breast-conserving treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Adjuvant radiotherapy in stage IV diffuse large cell lymphoma improves outcome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Survival of human glioma cells treated with various combination of temozolomide and X-rays

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Concomitant vinorelbine and radiation in head and neck squamous cell carcinoma in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non-small-cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Rationale for chemoradiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Farnesyltransferase inhibitors as radiation sensitizers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Therapeutic targeting of the tumor vasculature

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Disrupting tumour blood vessels

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Toxicity antagonists in head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Palifermin for oral mucositis after intensive therapy for hematologic cancers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Phase III randomized trial of amifostine as a radioprotector in head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Normal tissue effects: reporting and analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Toxicity in head and neck cancer: a review of trends and issues

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Chemotherapy and altered fractionation in head-and-neck cancer: in regard to Staar et al., IJROBP 2001;50:1161–1171

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Concomitant chemotherapy and radiation therapy certainly improves local control

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Chemotherapy and radiation of anal canal cancer: the first approach

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Combined radiotherapy and chemotherapy for anal cancer. EORTC Radiotherapy and Gastrointestinal Cooperative Groups

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Concurrent chemotherapy and radiation for locally advanced cervical cancer: the new standard of care

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Introducing the BECT (biologically enhanced cytotoxic treatment) concept in cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Investigation of relationship between change in locoregional control and change in overall survival in randomized controlled trials of modified radiotherapy in head-and-neck cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Epidermal Growth Factor Receptor Expression in Pretreatment Biopsies From Head and Neck Squamous Cell Carcinoma As a Predictive Factor for a Benefit From Accelerated Radiation Therapy in a Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Hypoxia--a key regulatory factor in tumour growth

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Radiosensitization of colon cancer cell lines by docetaxel: mechanisms of action

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Molecular biomarkers and site of first recurrence after radiotherapy for head and neck cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Radiation therapy: intensity modulated, image guided, biologically optimized and evidence based.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Theragnostic imaging for radiation oncology: dose-painting by numbers

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation O

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

A user's guide to evidence-based oncology

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0744

7 January 2021

Identifiers

DOI

10.1038/NCPONC0744

1 reference

Dimensions Publication ID

16 August 2017

0 references

1 reference